CHF Solutions, Inc. Appoints World-Renowned Heart Failure Cardiologist, Maria Rosa Costanzo, M.D. to Company’s Board of Dir...
September 04 2019 - 8:00AM
CHF Solutions, Inc. (Nasdaq:CHFS) today announced that Maria Rosa
Costanzo, M.D. has been appointed to the Company's Board of
Directors.
Dr. Costanzo is the medical director, Heart Failure Research, at
Advocate Heart Institute, and the medical director for Advanced
Heart Failure at Edward Hospital Center, both institutions located
in Chicago and in central Illinois. She is also a member of the
board of directors for the Heart Failure Society of America. In
addition, she is a member of several medical societies and a fellow
with the American College of Cardiology, American College of
Physicians, American Heart Association, and the European Society of
Cardiology, and a Gold Member of the Heart Failure Association of
the European Society of Cardiology. Dr. Costanzo has over 250
publications in peer reviewed journals, book chapters and
manuscripts. Dr. Costanzo received her medical degree with honors
from Facolta’ Di Medicina e Chirurgia dell’ Universita’ di Bologna,
Bologna, Italy.
"I am very pleased to have Dr. Costanzo join our Board of
Directors and look forward to her many contributions. Her
clinical expertise will be invaluable to CHF Solutions as we grow
and expand into new markets. Dr. Costanzo is recognized throughout
the world with the highest regard and with a position of
preeminence in cardio-renal syndrome," said John Erb, chairman and
CEO of CHF Solutions.
Dr. Costanzo commented, “I am excited about this opportunity to
join the Board of Directors. I believe that CHF Solutions is poised
for significant growth as it expands into cardiac surgery and the
pediatrics population. I look forward to contributing to the
strategic clinical and scientific direction of the company.”
About CHF SolutionsCHF Solutions, Inc.
(Nasdaq:CHFS) is a medical device company focused on developing,
manufacturing and commercializing the Aquadex FlexFlow® system for
aquapheresis therapy. The Aquadex FlexFlow system is a clinically
proven therapy that provides a safe, effective, and predictable
method of removing excess sodium and fluid from patients suffering
from fluid overload. The Aquadex FlexFlow system is indicated for
temporary (up to eight hours) ultrafiltration treatment of patients
with fluid overload who have failed diuretic therapy and extended
(longer than 8 hours) ultrafiltration treatment of patients with
fluid overload who have failed diuretic therapy and require
hospitalization. All treatments must be administered by a
healthcare provider, under physician prescription, both of whom
having received training in extracorporeal therapies. The company's
vision is to improve the lives of fluid overloaded patients through
science, collaboration, and innovative medical technology. CHF
Solutions is a Delaware corporation headquartered in Minneapolis,
Minnesota with wholly owned subsidiaries in Australia and Ireland.
The company has been listed on the Nasdaq Capital Market since
February 2012.
Forward-Looking StatementsCertain statements in
this release are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including
without limitation, statements regarding the potential growth of
the company. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this release, including, without limitation, those
risk associated with our ability to execute on our
commercialization strategy, the possibility that we may be unable
to raise sufficient funds necessary for our anticipated operations,
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
our ability to integrate acquired businesses, our expectations
regarding anticipated synergies with and benefits from acquired
businesses, and other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak only as
of the date when made. CHF Solutions does not assume any
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS:
INVESTORS: Claudia Napal Drayton Chief
Financial Officer CHF Solutions, Inc. 952-345-4205
ir@chf-solutions.com-or- Bret Shapiro Managing Partner CORE IR
516-222-2560 brets@coreir.com www.coreir.comMEDIA
Jules Abraham JQA Partners, Inc. 917-885-7378
jabraham@jqapartners.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024